GlycoMimetics is evaluating uproleselan to disrupt extrinsic factors of drug resistance in acute myeloid leukemia (AML).
Our pivotal trial for uproleselan is being conducted under the auspices of the FDA’s Breakthrough Therapy designation.
We are conducting
IND-enabling activities with
GMI-1687 for the treatment of
vaso-occlusive crisis in patients
with sickle cell disease.
We have applied our expertise in carbohydrate biology and chemistry to design highly potent, selective, and oral antagonists of galectin-3.
These therapies could be instrumental in treating fibrosis and various forms of cancer